OBJECTIVE: To determine incidence and early predictors of generalized @entity410 (GTCs) in @entity1 with @entity2048 ( @entity2048 ). METHODS: Occurrence of GTCs was determined in 446 @entity1 with @entity2048 who participated in a randomized clinical trial comparing ethosuximide, lamotrigine, and valproate as initial therapy for @entity2048 . RESULTS: As of June 2014, the cohort had been followed for a median of 7.0 years since enrollment and 12% (53) have experienced at least one GTC. The median time to develop GTCs from initial therapy was 4.7 years. The median age at first GTC was 13.1 years. Fifteen (28%) were not on medications at the time of their first GTC. On univariate analysis, older age at enrollment was associated with a higher risk of GTCs (p = -0.0009), as was the duration of the shortest burst on the baseline EEG (p = 0.037). Failure to respond to initial treatment (p < 0.001) but not treatment assignment was associated with a higher rate of GTCs. Among @entity1 initially assigned to ethosuximide, 94% (15/16) with GTCs experienced initial therapy failure (p < 0.0001). A similar but more modest effect was noted in those initially treated with valproate (p = 0.017) and not seen in those initially treated with lamotrigine. CONCLUSIONS: The occurrence of GTCs in a well-characterized cohort of @entity1 with @entity2048 appears lower than previously reported. GTCs tend to occur late in the course of the disorder. @entity1 initially treated with ethosuximide who are responders have a particularly low risk of developing subsequent GTCs.

Long-term outcomes of generalized @entity410 in a XXXX trial.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children'] @entity410 :: ('MESH:D012640', 'Disease') :: ['tonic-clonic seizures'] @entity2048 :: ('MESH:D004832', 'Disease') :: ['CAE', 'childhood absence epilepsy']
@entity2048 :: (MESH:D004832,Disease) :: ['childhood absence epilepsy']
